Diagnostic value and health economic analysis of multigene testing in thyroid nodules
Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]
- Issue:
- 2024 18
- Page:
- 3453-3459
- Research Field:
- Publishing date:
Info
- Title:
- Diagnostic value and health economic analysis of multigene testing in thyroid nodules
- Author(s):
- LUO Chengmin1; CHEN Baolin1; YAN Zhongliang1; BAO Yuxiang1; ZHANG Nengying1; 2; LI Jiayang3; LI Taolang1; CHENG Xiaoming1; LYU Junyuan1; 4
-
- Keywords:
- thyroid nodules; thyroid carcinoma; genetic testing; fine needle aspiration; health economics
- PACS:
- R736.1
- DOI:
- 10.3969/j.issn.1672-4992.2024.18.009
- Abstract:
- Objective:To investigate the value of multigene testing ［KRAS,NRAS,PIK3CA(H1047R) and BRAF(V600E),KNPB］ in the diagnosis of thyroid nodules.Methods:A total of 232 patients with thyroid nodules who underwent multigene testing from January 2020 to February 2021 were selected from our hospital.Clinical information was collected to analyse the mutation frequency of each gene in KNPB in thyroid nodules.The sensitivity,specificity,accuracy,positive predictive value,negative predictive value,cost-effectiveness ratio and incremental cost-effectiveness ratio of each test were compared using postoperative pathology as the "gold standard".Results:There were 251 nodules in 232 patients,with a total of 69(27.49%) BRAF(V600E)mutations,11(4.38%)KRAS mutations,9(3.59%) NRAS mutations,and no mutation detected in PIK3CA(H1047R).Among the 164 operated patients including 64 nodular goitres,9 thyroid adenomas,4 follicular thyroid carcinomas and 87 papillary thyroid carcinomas,the difference was statistically significant only for the BRAF(V600E) gene (P＜0.001).The area under the receiver operating characteristic(ROC) curve of fine needle aspiration cytology (FNAC) combined with BRAF(V600E) single gene detection was 0.856 and the incremental cost-effectiveness ratio was 98.81.Conclusion:Compared to multigenetesting,FNAC combined with BRAF(V600E) single gene detection has the best diagnostic performance and health economic value for thyroid nodules.
References:
［1］ 田文,孙辉,贺青卿.超声引导下甲状腺结节细针穿刺活检专家共识及操作指南(2018版)［J］.中国实用外科杂志,2018,38(03):241-244.TIAN W,SUN H,HE QQ.Expert consensus and operating guidelines forfine-needle aspiration biopsy of thyroid nodules under ultrasound guidance(2018 edition) ［J］.Chinese Journal of Practical Surgery,2018,38(03):241-244.
［2］ 王妍,梁瑞景,魏梦莹,等.多基因检测有助于甲状腺细针穿刺诊断不明确类型结节［J］.分子影像学杂志,2023,46(04):669-673.WANG Y,LIANG RJ,WEI MY,et al.Multigene testing is helpful for thyroid nodules diagnosed with unclear significance by fine needle aspiration［J］.Journal of Molecular Imaging,2023,46(04):669-673.
［3］ 史明明,宋以宁,邵光东,等.甲状腺癌多基因检测在甲状腺结节诊断中的应用［J］.中国现代普通外科进展,2023,26(08):644-647.SHI MM,SONG YN,SHAO GD,et al.Application of multi-gene detection of thyroid cancer in the diagnosis of thyroid nodules［J］.Chinese Journal of Current Advances in General Surgery,2023,26(08):644-647.
［4］ 宋丹琳,郑静,倪志鹏,等.超声图像人工智能辅助对甲状腺结节定性诊断价值的研究［J］.中国临床医学影像杂志,2023,34(02):87-90.SONG DL,ZHENG J,NI ZP,et al.Study on the qualitative diagnostic value of artificial intelligence-assisted ultrasound in characterizing thyroid nodules［J］.Journal of China Clinic Medical Imaging,2023,34(02):87-90.
［5］ 周武琳,程晓明,吕俊远,等.基于FNAB的分子检测技术在甲状腺结节诊断中的研究进展［J］.中国普通外科杂志,2021,30(05):613-621.ZHOU WL,CHENG XM,LV JY,et al.Research progress of molecular detection technologies based on FNAB in diagnosis of thyroid nodules［J］.China Journal of General Surgery,2021,30(05):613-621.
［6］ 中华人民共和国国家卫生健康委员会.甲状腺癌诊疗规范(2018年版)［J］.中华普通外科学文献(电子版),2019,13(01):1-15.National Health Commission of the People’s Republic of China.Standards for diagnosis and treatment of thyroid cancer (2018 Edition)［J］.Chinese Archivesof General Surgery(Electronic Edition),2019,13(01):1-15.
［7］ 杨淑娟,温圆圆,邵英,等.卫生经济决策模型的应用［J］.现代预防医学,2011,38(09):1650-1652.YANG SJ,WEN YY,SHAO Y,et al.Applicatipon of health economic decision analytical model［J］.Modern Preventive Medicine,2011,38(09):1650-1652.
［8］ GRANI G,SPONZIELLO M,PECCE V,et al.Contemporary thyroid nodule evaluation and management［J］.J Clin Endocrinol Metab,2020,105(9):2869-2883.
［9］ 鲁涛,高洁,周良锐,等.甲状腺癌RAS/BRAF/TERT基因突变与临床病理特征的关系［J］.诊断病理学杂志,2020,27(04):250-254.LU T,GAO J,ZHOU LR,et al.Gene mutation of RAS/BRAF/TERT and clinicopathological features in thyroid carcinoma［J］.Chinese Journal of Diagnostic Pathology,2020,27(04):250-254.
［10］ LIU S,ZHAO Y,LI M,et al.Simultaneous Hodgkin lymphoma and BRAFV600E-positive papillary thyroid carcinoma:a casereport［J］.Medicine (Baltimore),2019,98(3):e14180.
［11］ MOON S,SONG YS,KIM YA,et al.Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer:a meta-analysis［J］.Thyroid,2017,27(5):651-660.
［12］ ACQUAVIVA G,VISANI M,REPACI A,et al.Molecular pathology of thyroid tumours of follicular cells:a review of genetic alterations and their clinicopathological relevance［J］.Histopathology,2018,72(1):6-31.
［13］ GARCIA-ROSTAN G,COSTA AM,PEREIRA-CASTRO I,et al.Mutation of the PIK3CA gene in anaplastic thyroid cancer［J］.Cancer Res,2005,65(22):10199-10207.
［14］ 张富全,王兴越,高英堂,等.BRAF基因V600E突变与甲状腺乳头状癌关系的研究进展［J］.山东医药,2019,59(34):87-92.ZHANG FQ,WANG XY,GAO YT,et al.Research progress on the relationship between BRAF gene V600E mutation and papillary thyroid carcinoma［J］.Shandong Medical Journal,2019,59(34):87-92.
［15］ 宋创业,严丽,孟艳林,等.甲状腺癌发生发展及预后的相关影响因素［J］.中华普通外科学文献(电子版),2020,14(01):72-75.SONG CY,YAN L,MENG YL,et al.Related factors of occurrence,development and prognosis of thyroid cancer［J］.Chinese Archives of Genera Surgery(Electronic Edition),2020,14(01):72-75.
［16］ CRISPO F,NOTARANGELO T,PIETRAFESA M,et al.BRAF inhibitors in thyroid cancer:clinical impact,mechanisms of resistance and future perspectives［J］.Cancers (Basel),2019,11(9):1388.
［17］ ZHANG Q,LIU SZ,ZHANG Q,et al.Meta-analyses of association between BRAF(V600E)mutation and clinicopathological features of papillary thyroid carcinoma［J］.Cell Physiol Biochem,2016,38(2):763-776.
［18］ ELISEI R,VIOLA D,TORREGROSSA L,et al.The BRAF(V600E) mutation is an independent,poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma:single-institution results from a large cohort study［J］.J Clin Endocrinol Metab,2012,97(12):4390-4398.
［19］ ELISEI R,UGOLINI C,VIOLA D,et al.BRAF (V600E) mutation and outcome of patients with papillary thyroid carcinoma:a 15-year median follow-upstudy［J］.J Clin Endocrinol Metab,2008,93(10):3943-3949.
［20］ 张毓.锥光束乳腺CT、钼靶、超声及磁共振对乳腺病变的诊断价值研究及卫生经济学评价［D］.广西：广西医科大学，2021.ZHANG S.The diagnostic value of cone-beam breast CT,mammography,ultrasoundand and MRI in breast lesions and evaluation of health economics［D］.Guangxi:Guangxi Medical University,2021.
［21］ 陶立波,刘畅.增量成本效果比（ICER）的决策含义辨析［J］.中国医疗保险，2021(04):66-68.TAO LB,LIU C.Discrimination in decision making implications of incremental cost effectiveness ratio (ICER)［J］.China Health Insurance,2021(04):66-68.
［22］ 张楠,石学峰,吴晶.增量成本效果比在卫生技术评估中的应用［J］.中国卫生政策研究,2012,5(02):64-68.ZHANG N,SHI XF,WU J.The application of incremental cost-effectiveness ratio to health technology assessment［J］.Chinese Journal of Health Policy,2012,5(02):64-68.
Memo
- Memo:
- -